India’s Pharmacy Market: Entero vs. Medplus Battle

India’s pharmacy retail and distribution market, a sector valued at approximately US$24-27 billion (₹2.3 lakh crore), is experiencing significant transformation. This robust growth, marked by a 10% CAGR, is attracting substantial investment from key players like Entero Healthcare Solutions and Medplus Health Services, who are strategically vying for market share.

Market Dynamics Underpinning Growth

The expansion of India’s pharmacy landscape is fueled by several interconnected factors. Increased healthcare spending, a rising prevalence of chronic diseases, and the strategic expansion of organized pharmacy chains are all contributing to this dynamic environment.

• Increasing healthcare spending
• Prevalence of chronic diseases
• Expansion of organized pharmacy chains and digital platforms

These drivers necessitate a focus on technology, extensive store networks, efficient inventory management, and robust home delivery capabilities for market leaders.

Entero Healthcare’s Strategic Pivot

Entero Healthcare Solutions, a prominent healthcare product distributor, operates with a dual business model encompassing core distribution and integrated commercial solutions. As of Q1FY27, the company serves over 72,000 retail pharmacies and 2,300 hospitals, distributing a wide array of healthcare products.

The company differentiates itself by leveraging technology-enabled supply chain solutions to actively generate demand for healthcare brands. Their Q1FY27 performance highlights this effectiveness, showcasing strong revenue and profit growth.

• Revenue Growth: 38.2% year-on-year to ₹1,940 crore
• Organic Growth: 17.8% (19.6% like-for-like), surpassing the Indian Pharmaceutical Market’s 13.8% growth
• EBITDA Margin Expansion: 143 bps to 5.0%
• Net Profit Increase: 73.3% to ₹52 crore

Entero attributes this growth to an expanding customer base, increased customer wallet share, and superior product availability. The company is also strategically pivoting towards higher-margin MedTech segments, including In Vitro Diagnostics (IVD), Cardiovascular, Orthopedic devices, Surgical Consumables, and Imaging.

Capital rationalization is another key strategic pillar, with a focus on organic growth and integrating existing operations, reflected by zero new acquisitions in Q1FY27 after 51 prior acquisitions. For FY27, Entero projects 23% revenue growth (excluding new acquisitions) and 5% margins, with an anticipated 20%+ annual organic growth over the next 3-4 years and a 50% EBITDA-to-operating cash flow conversion rate.

Medplus Health’s Ambitious Expansion

Medplus Health Services, recognized as India’s second-largest pharmaceutical retailer, pioneered the omni-channel pharmacy model. By June 30, 2026, Medplus operated 5,476 stores across 13 states and one union territory, demonstrating a significant retail footprint.

The company harbors an ambitious long-term goal of expanding its network to between 20,000 and 40,000 stores nationwide. Its expansion strategy employs a cluster-based approach, prioritizing densification in existing Metro and Tier-1 cities before venturing into Tier-2 areas.

• Current Stores: 5,476 (June 30, 2026)
• Long-term Goal: 20,000 to 40,000 stores
• Store Level ROCE (Mature Stores): Exceeds 60%
• New Store Profitability: Achieved within 24 months

Medplus also emphasizes high-margin private label products, which constituted 20% of its Q1FY27 revenue. This segment includes both pharma (10.7%) and non-pharma (9.3%) offerings. Additionally, the company is actively scaling its diagnostics business, signaling a broader healthcare services strategy.

The Path Ahead

Both Entero Healthcare Solutions and Medplus Health Services are demonstrating clear, albeit distinct, strategies to capture the expanding Indian pharmacy market. Their focus on operational efficiency, strategic pivots to higher-margin segments, and aggressive expansion plans underscore the competitive dynamics shaping this vital sector.